LTX-315
DRACPC ID DRACPC0088
Active Ingredients LTX-315
Description A peptide derived from human lactoferrin, with potential lytic and immunostimulating activities. Upon transdermal injection directly into the tumor, ruxotemitide may bind to the tumor cell membranes and subsequently lyse tumor cells, thereby inducing tumor cell necrosis. In turn, presentation of the tumor antigens to the immune system may induce systemic innate and adaptive immune responses mediated by anti-tumor natural killer (NK) cells, cytotoxic T lymphocytes, and natural killer T (NKT) cells. This may trigger an immune response against tumor associated antigens on tumors distant from the primary tumor. Human lactoferrin, a 692 amino acid glycoprotein, belongs to the transferrin family of metal-binding proteins.
Synonyms Oncopore; Ruxotemitide; LTX-315
Type Small Molecule
Disease Lymphoma, Melanoma, Carcinoma, Breast Cancer
Classification
Peptide and derivative
Structure Information
Molecular Formula C78H106N18O9
Molecular Weight 1439.8
Active Sequence KKWWKKWXK
Sequence Length 9
Modification X=Dip, N-terminal NH2
IUPAC Name (2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2,6-diaminohexanamido]hexanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]hexanamido]hexanamido]-3-(1H-indol-3-yl)propanamido]-3,3-diphenylpropanamido]hexanamide
InChI InChI=1S/C78H106N18O9/c79-38-18-13-30-57(84)71(98)90-62(35-15-20-40-81)73(100)93-66(44-52-47-87-59-32-11-8-28-55(52)59)76(103)95-65(43-51-46-86-58-31-10-7-27-54(51)58)75(102)92-63(36-16-21-41-82)72(99)91-64(37-17-22-42-83)74(101)94-67(45-53-48-88-60-33-12-9-29-56(53)60)77(104)96-69(78(105)89-61(70(85)97)34-14-19-39-80)68(49-23-3-1-4-24-49)50-25-5-2-6-26-50/h1-12,23-29,31-33,46-48,57,61-69,86-88H,13-22,30,34-45,79-84H2,(H2,85,97)(H,89,105)(H,90,98)(H,91,99)(H,92,102)(H,93,100)(H,94,101)(H,95,103)(H,96,104)/t57-,61-,62-,63-,64-,65-,66-,67-,69-/m0/s1
InChI_Key GGAKLYWEFZCVIT-TVEKFXMRSA-N
SMILES NCCCC[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](N)CCCCN)=O)CCCCN)=O)CC1=CNC2=C1C=CC=C2)=O)CC3=CNC4=CC=CC=C34)=O)C(N[C@@H](CCCCN)C(N[C@H](C(N[C@@H](C(C5=CC=CC=C5)C6=CC=CC=C6)C(N[C@H](C(N)=O)CCCCN)=O)=O)CC7=CNC8=C7C=CC=C8)=O)=O
External Codes
PubChem CID 46200994
DrugBank Accession Number DB12748
NCI Thesaurus Code C90547
UNII 75FBL12IZ7 GSRS
CAS 1345407-05-7
Drug approval
Drug indication
LTX-315 has been used in trials studying the treatment of Cancer, Lymphoma, Melanoma, Carcinoma, and Breast Cancer, among others.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT01058616 | Phase 1 Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour | Cancer With Transdermal Accessible Tumour | Phase 1 | Treatment |
| NCT01986426 | A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumours | Cancer; Melanoma; Breast Cancer; Head and Neck Cancer; Lymphoma; Triple-Negative Breast Cancer | Phase 1 | Treatment |
| NCT01223209 | A Phase I, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma | Carcinoma | Phase 1 | Treatment |
| NCT04796194 | A Phase II Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to Pembrolizumab | Advanced Melanoma | Phase 2 | Treatment |
| NCT03725605 | An Open Label Phase II Single Centre Study Investigating the Safety and Efficacy of LTX-315 and Adoptive T-cell Therapy in Patients With Advanced/Metastatic Soft Tissue Sarcoma (ATLAS-IT-04) | Soft Tissue Sarcoma | Phase 2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
